Cinryze Subcu Unlikely to enter market until 2016 or 2017...another mañana story!!
The company was told by the FDA that the hurdles for approving its subcutaneous formulation of Cinryze would be higher than the current intravenous formulation. Any subcutaneous formulation of a C1 inhibitor is unlikely to enter the market until 2016 or 2017, making the threat of direct competition to ViroPharma's own plans for developing a subcutaneous version of Cinryze less of a threat than it appears on the surface.
There is no doubt that any biopharma is going to have a pipeline that can extend for years. The key is for them to become cash flow positive before they run out of cash and have to dilute existing shareholders to keep the doors open.
They have about 18 months runway before they start to run out of cash. If they get a few milestone payments they can probably eke out 24 months. I had thought they were going to sell their own direct product, but that never seems to have gained any real traction??